Immuneering Corp
Immuneering is a clinical-stage oncology company developing oral small-molecule cancer medicines called Deep Cyclic Inhibitors. Its drug candidates are designed to disrupt cancer signaling pathways, including the MAPK pathway. The lead candidate, atebimetinib, is an oral, once-daily MEK inhibitor being studied for advanced solid tumors, including pancreatic cancer. Immuneering is initiating a Phase 3 trial evaluating it with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer. Its second clinical-stage candidate, envometinib, is an allosteric MEK inhibitor; the company has paused its internal development and is pursuing partnership opportunities. Immuneering also has earlier-stage discovery programs targeting other cancer-signaling pathways. The company uses bioinformatics and proprietary 3D tumor models to guide drug discovery and development. It previously provided translational bioinformatics services to pharmaceutical and biotechnology companies, but has since ceased that business. Immuneering is headquartered in Cambridge, Massachusetts.
No SEC Form 4 filings for $IMRX in the last 30 days.
See all $IMRX insider activity →Immuneering Corporation (IMRX) reported a Q3 GAAP EPS of -$0.37, missing estimates by $0.06. The company had $166.1 million in cash and equivalents as of September 30, 2026, down from $217.0 million at the end of 2025.
Immuneering reported a net loss of $24.19M for 2026, up 61.7% from 2025. Revenue was $24.34M, down 62.6% YoY. The company began dosing for MAPKeeper 301, increased enrollment, and plans further trials for atebimetinib combinations. Phase 2 data is expected in 2027.
Immuneering Corp (IMRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates - Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning IMRX (Immuneering Corp). Coverage has been balanced: 1 bullish, 3 neutral, and 1 bearish.
Recent IMRX coverage spans earnings, insider activity and corporate actions.
Earnings miss likely triggers sell pressure.
The earnings miss and loss pressure the stock, but accelerated trial enrollment and positive Phase 2 survival data could attract biotech investors.
Positive trial progress and extended cash runway suggest upside potential.
The trial start adds a material catalyst that could drive the stock higher if data are positive.
New Buy initiation may spark trading interest, especially in smaller-cap biotech.
AlphAI scores every news story that mentions IMRX with an AI model for sentiment and relevance, and aggregates insider trades from Immuneering Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Immuneering Corporation (IMRX) reported a Q3 GAAP EPS of -$0.37, missing estimates by $0.06. The company had $166.1 million in cash and equivalents as of September 30, 2026, down from $217.0 million at the end of 2025.
2 min readImmuneering reported a net loss of $24.19M for 2026, up 61.7% from 2025. Revenue was $24.34M, down 62.6% YoY. The company began dosing for MAPKeeper 301, increased enrollment, and plans further trials for atebimetinib combinations. Phase 2 data is expected in 2027.
1 min readImmuneering Corp (IMRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates - Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N
2 min readImmuneering (IMRX) began dosing in its Phase 3 trial (MAPKeeper 301) for first-line pancreatic cancer, testing atebimetinib+mGnP vs GnP. The study, recruiting now, aims to improve overall survival. Positive results could significantly impact the company's stock.
1 min read24/7 Wall St. lists Thursday analyst calls. JPMorgan upgraded Charles River Laboratories (CRL) to Overweight, target $310. Wolfe raised Global Payments (GPN) to Outperform, target $110. Argus upgraded Roper Technologies (ROP) to Buy, target $450. Piper cut AppLovin (APP) to Neutral, target $385, and HubSpot (HUBS) to Neutral, target $220. Several other upgrades, downgrades, and initiations are noted.
4 min readImmuneering Corp (IMRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates - 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO
6 min readZeskind Benjamin J. (PRESIDENT AND CEO) purchased 2,400 shares of Immuneering Corp (IMRX) at $4.56 on 2026-06-23.
2 min readHall Brett Matthew (CHIEF SCIENTIFIC OFFICER) purchased 6,035 shares of Immuneering Corp (IMRX) at $4.15 on 2026-06-15.
2 min readImmuneering Corp (IMRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. imrx-20260611 0001790340 FALSE 0001790340 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K __________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
2 min readImmuneering Corp (IMRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. imrx-20260611 0001790340 FALSE 0001790340 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K __________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
2 min read
